Watershed Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$870K
- Investors
-
15
Watershed Therapeutics General Information
Description
Developer of a targeted drug delivery technology designed to deliver long-term therapies directly to the bladder with minimal procedures and improved patient comfort. The company offers localized delivery systems for the prevention of bladder cancer, overactive bladder, and recurrent urinary tract conditions, enabling urologists and patients to achieve sustained treatment effectiveness with reduced procedural burden.
Contact Information
Website
www.watershedtx.comCorporate Office
- 454 North 34th Street
- Seattle, WA 98103
- United States
Corporate Office
- 454 North 34th Street
- Seattle, WA 98103
- United States
Watershed Therapeutics Timeline
Watershed Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Equity Crowdfunding | 01-May-2026 | $870K | Completed | Clinical Trials - Phase 1 | ||
| 7. Later Stage VC | 04-Apr-2026 | Completed | Clinical Trials - Phase 1 | |||
| 6. Seed Round | 01-Nov-2025 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 01-Jan-2025 | Completed | Clinical Trials - Phase 1 | |||
| 4. Seed Round | 07-Apr-2024 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 10-Jan-2024 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Sep-2022 | $3.67M | Completed | Pre-Clinical Trials | ||
| 1. Seed Round | 15-Aug-2022 | $3.67M | $3.67M | Completed | Pre-Clinical Trials |
Watershed Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series CF | ||||||||
| Seed-4 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | ||||||||
| Seed-1 | 212,689 | $0.000100 | $0.04 | $0.45 | $0.45 | 1x | $0.45 | 1.12% |
| Bridge | 2,542,684 | $0.000100 | $0.08 | $1.05 | $1.05 | 1x | $1.05 | 13.4% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Watershed Therapeutics Comparisons
Industry
Financing
Details
Watershed Therapeutics Competitors (7)
One of Watershed Therapeutics’s 7 competitors is Trigone Pharma, a Corporation company based in Raanana, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Trigone Pharma | Corporation | Raanana, Israel | ||||
| EnGene Therapeutics | Formerly VC-backed | Saint-Laurent, Canada | ||||
| Urogen Pharma | Formerly VC-backed | Princeton, NJ | ||||
| Relmada Therapeutics | Formerly VC-backed | Coral Gables, FL | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA |
Watershed Therapeutics Patents
Watershed Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260315764-A1 | System and method for sustained release of agents in the bladder | Pending | 09-Apr-2025 | ||
| WO-2026217851-A1 | System and method for sustained release of agents in the bladder | Pending | 09-Apr-2025 | ||
| AU-2024311211-A1 | System and method for sustained release of agents in the bladder | Pending | 30-Jun-2023 | ||
| EP-4734966-A2 | System and method for sustained release of agents in the bladder | Pending | 30-Jun-2023 | ||
| WO-2025007091-A2 | System and method for sustained release of agents in the bladder | Inactive | 30-Jun-2023 | A61P31/00 |
Watershed Therapeutics Signals
Watershed Therapeutics Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Device of Tomorrow Capital | Venture Capital | Minority | ||
| Highcroft Capital | Venture Capital | Minority | ||
| U.S. Department of Health and Human Services | Government | |||
| Charleston Angel Partners | Angel Group | Minority | ||
| Serial Stage Venture Partners | Venture Capital | Minority |
Watershed Therapeutics FAQs
-
When was Watershed Therapeutics founded?
Watershed Therapeutics was founded in 2019.
-
Where is Watershed Therapeutics headquartered?
Watershed Therapeutics is headquartered in Seattle, WA.
-
What is the size of Watershed Therapeutics?
Watershed Therapeutics has 7 total employees.
-
What industry is Watershed Therapeutics in?
Watershed Therapeutics’s primary industry is Drug Delivery.
-
Is Watershed Therapeutics a private or public company?
Watershed Therapeutics is a Private company.
-
What is the current valuation of Watershed Therapeutics?
The current valuation of Watershed Therapeutics is .
-
What is Watershed Therapeutics’s current revenue?
The current revenue for Watershed Therapeutics is .
-
How much funding has Watershed Therapeutics raised over time?
Watershed Therapeutics has raised $10.1M.
-
Who are Watershed Therapeutics’s investors?
Device of Tomorrow Capital, Highcroft Capital, U.S. Department of Health and Human Services, Charleston Angel Partners, and Serial Stage Venture Partners are 5 of 15 investors who have invested in Watershed Therapeutics.
-
Who are Watershed Therapeutics’s competitors?
Trigone Pharma, EnGene Therapeutics, Urogen Pharma, Relmada Therapeutics, and ImmunityBio are some of the 7 competitors of Watershed Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process